Synergy Pharmaceuticals (SGYP) Earning Somewhat Positive News Coverage, Report Shows
Headlines about Synergy Pharmaceuticals (NASDAQ:SGYP) have trended somewhat positive this week, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Synergy Pharmaceuticals earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.5018434484335 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern’s scoring:
- Synergy Pharma (SGYP) Presents At Cantor Fitzgerald Global Healthcare Conference – Slideshow (seekingalpha.com)
- Synergy Pharma (SGYP) Presents At Ladenburg Thalmann 2017 Healthcare Conference – Slideshow (seekingalpha.com)
- Why H.C. Wainwright Just Cut Price Target on Synergy Pharmaceuticals Inc (SGYP) by 50% (smarteranalyst.com)
- Synergy Pharmaceuticals Inc. (SGYP) and Finisar Corporation (FNSR) Grabbing Attentions on Risk Factor – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Analyst’s Buy rated Healthcare Stock: Synergy Pharmaceuticals Inc. (SGYP) – Street Observer (press release) (streetobserver.com)
Shares of Synergy Pharmaceuticals (NASDAQ SGYP) traded up 11.97% during trading on Friday, reaching $2.90. The company had a trading volume of 10,848,161 shares. Synergy Pharmaceuticals has a 12 month low of $2.57 and a 12 month high of $7.15. The firm’s market capitalization is $652.37 million. The stock has a 50 day moving average price of $3.07 and a 200 day moving average price of $4.01.
Synergy Pharmaceuticals (NASDAQ:SGYP) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.08). The firm had revenue of $2.31 million during the quarter, compared to analyst estimates of $1.98 million. During the same quarter in the previous year, the company posted ($0.23) EPS. On average, equities research analysts forecast that Synergy Pharmaceuticals will post ($1.16) EPS for the current year.
SGYP has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $11.00 target price on shares of Synergy Pharmaceuticals in a research note on Friday, September 8th. Oppenheimer Holdings, Inc. reduced their target price on Synergy Pharmaceuticals from $9.00 to $6.00 and set an “outperform” rating for the company in a research note on Friday, September 8th. ValuEngine cut Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. BTIG Research restated a “buy” rating and set a $11.00 price objective on shares of Synergy Pharmaceuticals in a research note on Friday, September 8th. Finally, Zacks Investment Research upgraded Synergy Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. Synergy Pharmaceuticals has an average rating of “Hold” and a consensus target price of $8.68.
In other news, major shareholder Paulson & Co. Inc. sold 26,287 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $3.77, for a total transaction of $99,101.99. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 3.80% of the company’s stock.
About Synergy Pharmaceuticals
Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.
Receive News & Stock Ratings for Synergy Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.